NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: IPCALAB · data 2026-10-30
IPCA Laboratories Limited
In plain words
Price: 5.4% below its 52-week high of ₹2,038.
Delivery: 51.3% of traded shares were kept for delivery over the last 10 sessions, against 52.9% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹10,126 cr |
| Net profit (last 12 months) | ₹1,310 cr |
| Sales growth, 3 years (yearly) | 15.6% |
| Profit growth, 3 years (yearly) | 34.3% |
Smart-money activity
28/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 10/30: Delivery 55.6% over the last 20 sessions vs 36.3% in the 40 before (1.53x); shares delivered per day 0.79x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 11/15: 19 schemes hold it, about ₹1,374 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 2/15: Verdict "None", sustained score 56/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend
- 7 Aug 26Dividend Dividend ₹6 (ex-date) -2.8% next session
- 5 Aug 25Dividend Dividend ₹2 (ex-date) -3.9% next session
- 27 Nov 24Dividend Dividend ₹2 (ex-date) -3.4% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Common questions
Is IPCA Laboratories Limited debt-free?
Its latest reported debt-to-equity ratio is 0.1.
What is IPCA Laboratories Limited's P/E ratio?
About 37.3, based on the last 12 months' earnings and a price of ₹1,927.8 (data 2026-10-30).
What is the 52-week high and low of IPCA Laboratories Limited?
The 52-week high is ₹2,038 and the 52-week low is ₹1,270.
Mutual funds holding IPCA Laboratories Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 19 schemes holding about ₹1,374 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| Nippon India Growth Mid Cap Fund | Nippon India Mutual Fund | 1.19% | ₹597 cr |
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 2.87% | ₹263 cr |
| Mirae Asset Healthcare Fund | Mirae Asset Mutual Fund | 3.39% | ₹119 cr |
| Nippon India Balanced Advantage Fund | Nippon India Mutual Fund | 0.85% | ₹81 cr |
| ADITYA BIRLA SUN LIFE MIDCAP FUND | Aditya Birla Sun Life Mutual Fund | 0.85% | ₹56 cr |
| ADITYA BIRLA SUN LIFE MULTI ASSET ALLOCATION FUND | Aditya Birla Sun Life Mutual Fund | 0.68% | ₹51 cr |
| Nippon India Vision Large & Mid Cap Fund | Nippon India Mutual Fund | 0.65% | ₹48 cr |
| Nippon India Nifty Pharma ETF | Nippon India Mutual Fund | 2.71% | ₹47 cr |
| ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND | Aditya Birla Sun Life Mutual Fund | 2.71% | ₹29 cr |
| Nippon India ETF Nifty Midcap 150 | Nippon India Mutual Fund | 0.66% | ₹25 cr |
| Nippon India Nifty Midcap 150 Index Fund | Nippon India Mutual Fund | 0.66% | ₹18 cr |
| Nippon India Active Momentum Fund | Nippon India Mutual Fund | 2.08% | ₹12 cr |
| Mirae Asset Nifty Midcap 150 ETF | Mirae Asset Mutual Fund | 0.66% | ₹12 cr |
| SBI Nifty Midcap 150 Index Fund | SBI Mutual Fund | 0.66% | ₹8 cr |
| ADITYA BIRLA SUN LIFE NIFTY MIDCAP 150 INDEX FUND | Aditya Birla Sun Life Mutual Fund | 0.66% | ₹3 cr |
Similar companies
Biocon Limited (BIOCON) · Abbott India Limited (ABBOTINDIA) · Gland Pharma Ltd. (GLAND) · Ajanta Pharma Limited (AJANTPHARM) · GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open IPCALAB in NSE Scanner →